Treatment of NSCLC with bintrafusp alfa (M7824) targeting PD‐L1 and TGF‐β simultaneously has shown to block tumor mesenchymalization and PD‐L1‐dependent immunosuppression and dominated chemoresistance [266]. This evidence concerns the gene CD274 and neoplasm.